-
Mercados
-
Acções
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
índices
A milestone in a decade of transformationEuronext joins the CAC 40®Read moreAs of 22 September 2025, Euronext has officially joined the CAC 40®, France’s flagship blue-chip index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fundos
-
Obrigações
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Warrants & Certificados
-
Derivados
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Matérias-Primas
- Vista global
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Entrega e liquidação
- Especificações e disposições
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Recursos
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
ERYtech Pharma
Identification
Instrument name
ERYTECH PHARMA
Symbol
ERYPA
ISIN code
FR0011471135
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Pharmaceuticals
Activity description
ERYtech Pharma est spécialisé dans le développement et la fabrication de produits thérapeutiques destinés au traitement des pathologies graves, des indications orphelines ou des sous-populations de patients notamment dans les domaines de l'hématologie, du cancer et des maladies métaboliques. Par ailleurs, le groupe propose des prestations de recherche et de développement pour compte de tiers.
Source : Cofisem
Website address
http://www.erytech.com
Operation
IPO date
Ter 07/05/2013
IPO type
Introduction par offre au public
Catégorie
IPO
Operation calendar
30 APR 2013 Listing
07 MAY 2013 Trading
Price range
Prix d'émission: 10,50 - 12,70 EUR
Capital raised
17,68